NutriBand (NTRB) Cash from Financing Activities (2016 - 2026)
NutriBand's (NTRB) quarterly Cash from Financing Activities came in at -$5490.0 in Q1 2026, up 96.27% year-on-year from -$2797.2 in Q1 2025, and down 107.89% quarter-over-quarter from $69563.0 in Q4 2025.
NutriBand (NTRB) Cash from Financing Activities (2016 - 2026) Analysis & Trends
NutriBand has disclosed Cash from Financing Activities across 11 years of filings, most recently posting -$5490.0 for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$5490.0, up 96.27% year-over-year; the trailing twelve-month figure through Jan 2026 was $5.4 million (down 36.71% YoY), and the FY2026 annual result was $5.4 million, down 36.71% from the prior year.
- Cash from Financing Activities came in at -$5490.0 for Q1 2026 at NutriBand, down from $69563.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $8.7 million in Q2 2024 to a low of -$147224.0 in Q1 2025.
- The 5-year median for Cash from Financing Activities is -$5004.0 (2024), against an average of $991558.1.
- Peak annual rise in Cash from Financing Activities reached 104156.56% in 2025, while the deepest fall reached 2842.13% in 2025.
- NutriBand's Cash from Financing Activities stood at -$6525.0 in 2022, then gained by 23.98% to -$4960.0 in 2023, then retreated by 4.33% to -$5175.0 in 2024, then jumped by 1444.21% to $69563.0 in 2025, then plunged by 107.89% to -$5490.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$5490.0 (Q1 2026), $69563.0 (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | NutriBand | 41.91 Mn | 37.33 Mn | 88,941.00 | -5,490.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -5,490.00 |
| Jan 31, 2026 | -5,490.00 |
| Oct 31, 2025 | 69,563.00 |
| Oct 31, 2025 | 69,563.00 |
| Jul 31, 2025 | 5.34 Mn |
| Jul 31, 2025 | 5.34 Mn |
| Apr 30, 2025 | -5,326.00 |
| Apr 30, 2025 | -5,326.00 |
| Jan 31, 2025 | -147,224.00 |
| Jan 31, 2025 | -147,224.00 |
| Oct 31, 2024 | -5,175.00 |
| Oct 31, 2024 | -5,175.00 |
| Jul 31, 2024 | -5,136.00 |
| Jul 31, 2024 | -5,136.00 |
| Apr 30, 2024 | 8.69 Mn |
| Apr 30, 2024 | 8.69 Mn |
| Jan 31, 2024 | -5,004.00 |
| Jan 31, 2024 | -5,004.00 |
| Oct 31, 2023 | -4,960.00 |
| Oct 31, 2023 | -4,960.00 |